Dean Ross, MD
Family Medicine · Oklahoma City, OKNPI 1952347361
Payments from drug & device makers
Across 215 payments — averaging $14.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$378
- Novo Nordisk$317
- Lilly USA, LLC$310
- AstraZeneca$287
- Boehringer Ingelheim$214
- AbbVie$195
- plus $1K from 25 others
What the payments were for
- Food & beverage$3,05498%
- Education$622%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 51 | $378 |
| Novo Nordisk | 22 | $317 |
| Lilly USA, LLC | 19 | $310 |
| AstraZeneca | 14 | $287 |
| Boehringer Ingelheim | 12 | $214 |
| AbbVie(2 entities) | 9 | $195 |
| GSK | 11 | $184 |
| Amgen | 8 | $162 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $162 |
| Abbott | 8 | $152 |
| Merck | 18 | $142 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $103 |
| Sanofi-aventis U.S. LLC | 4 | $66 |
| Exact Sciences | 3 | $58 |
| Currax Pharmaceuticals LLC | 2 | $50 |
| Bayer | 3 | $50 |
| Nevro Corp. | 1 | $25 |
| Bausch Health US, LLC | 1 | $25 |
| Vanda Pharmaceuticals Inc. | 1 | $24 |
| Ultragenyx Pharmaceutical Inc. | 1 | $24 |
| Eisai Inc. | 1 | $23 |
| Corcept Therapeutics | 1 | $23 |
| Bristol Myers Squibb | 1 | $21 |
| Hologic Sales And Service, LLC | 1 | $20 |
| Novartis | 1 | $19 |
| Medtronic | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Dexcom, Inc. | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $13 |
| Antares Pharma, Inc. | 1 | $12 |
| Johnson & Johnson | 1 | $11 |
How this compares
$3,115 in reported general payments places this provider in the 80th percentile of 1,730 family medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 141 | $161,950 |
| EliquisApixaban | 192 | $144,929 |
| MounjaroTirzepatide | 131 | $143,887 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 91 | $87,260 |
| JardianceEmpagliflozin | 90 | $85,862 |
| TrulicityDulaglutide | 69 | $84,157 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 88 | $62,544 |
| JanuviaSitagliptin Phosphate | 52 | $56,754 |
| LinzessLinaclotide | 80 | $51,752 |
| Dupixent SyringeDupilumab | 13 | $48,626 |
| MyrbetriqMirabegron | 68 | $39,468 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 36 | $36,766 |
| FarxigaDapagliflozin Propanediol | 54 | $35,791 |
| Xigduo XrDapaglifloz Propaned/Metformin | 44 | $27,094 |
| Breo ElliptaFluticasone/Vilanterol | 49 | $24,386 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $310 | $233,989225 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance, Tradjenta, Stiolto Respimat, Synjardy | $214 | $219,693250 claims |
| Novo NordiskOzempic, Rybelsus | $317 | $174,949153 claims |
| PfizerEliquis, Premarin | $378 | $154,559214 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $184 | $98,813157 claims |
| MerckJanuvia, Janumet Xr | $142 | $93,52088 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $287 | $57,09688 claims |
| AbbVieLinzess | $195 | $51,75280 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $162 | $6,20017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Oklahoma City
- Carl GriffinOklahoma City$28.2M
- Alexander FrankOklahoma City$3.1M
- Charles LunnOklahoma City$1.4M
- Hieu NguyenOklahoma City$238K
- Melinda CailOklahoma City$122K
- Jose Maria Borrego AcostaOklahoma City$106K
- Brett CauthenOklahoma City$77K
- Angelique BarretoOklahoma City$74K
- John PittmanOklahoma City$39K
- Terrence TruongOklahoma City$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.